Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume 16, Issue 2, Pages 237-248
Publisher
Wiley
Online
2011-08-20
DOI
10.1111/j.1582-4934.2011.01415.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Myeloproliferative disorder FOP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cγ at the centrosome
- (2012) Hélène Lelièvre et al. Molecular Cancer
- JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma
- (2011) K. Van Roosbroeck et al. BLOOD
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
- (2011) Wayne W. Chan et al. CANCER CELL
- Targeting myeloproliferative neoplasms with JAK inhibitors
- (2011) Animesh Pardanani et al. CURRENT OPINION IN HEMATOLOGY
- Multiple oligomerization domains of KANK1-PDGFR are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK
- (2011) S. Medves et al. HAEMATOLOGICA
- The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)
- (2011) B. Wasag et al. HAEMATOLOGICA
- The t(1;9)(p34;q34) fusing ABL1 with SFPQ, a pre-mRNA processing gene, is recurrent in acute lymphoblastic leukemias
- (2011) Francois P. Duhoux et al. LEUKEMIA RESEARCH
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bag1 directly routes immature BCR-ABL for proteasomal degradation
- (2010) F. Tsukahara et al. BLOOD
- New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases
- (2010) F. Toffalini et al. BLOOD
- ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
- (2010) David E. Gerber et al. CANCER CELL
- Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy
- (2010) James R Porter et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Stat5 is indispensable for the maintenance ofbcr/abl-positive leukaemia
- (2010) Andrea Hoelbl et al. EMBO Molecular Medicine
- Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib
- (2010) M. Koldehoff et al. HAEMATOLOGICA
- Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis
- (2010) P. Erben et al. HAEMATOLOGICA
- Critical Role of the Platelet-derived Growth Factor Receptor (PDGFR) β Transmembrane Domain in the TEL-PDGFRβ Cytosolic Oncoprotein
- (2010) Federica Toffalini et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma
- (2010) Konstanze Pechloff et al. JOURNAL OF EXPERIMENTAL MEDICINE
- KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia
- (2010) S Medves et al. LEUKEMIA
- ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1
- (2010) M Thai et al. LEUKEMIA
- Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
- (2010) Jianming Zhang et al. NATURE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data
- (2010) Ahmed Essaghir et al. NUCLEIC ACIDS RESEARCH
- DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells
- (2010) M Gandhi et al. ONCOGENE
- As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia
- (2010) J.-H. Mao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The juxtamembrane domain in ETV6/FLT3 is critical for PIM-1 up-regulation and cell proliferation
- (2009) Hoang Anh Vu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Anaplastic lymphoma kinase: signalling in development and disease
- (2009) Ruth H. Palmer et al. BIOCHEMICAL JOURNAL
- Over half of breakpoints in gene pairs involved in cancer-specific recurrent translocations are mapped to human chromosomal fragile sites
- (2009) Allison A Burrow et al. BMC GENOMICS
- Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia
- (2009) Franz Gruber et al. BRITISH JOURNAL OF HAEMATOLOGY
- Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen
- (2009) E. Lierman et al. HAEMATOLOGICA
- The fusion proteins TEL-PDGFR and FIP1L1-PDGFR escape ubiquitination and degradation
- (2009) F. Toffalini et al. HAEMATOLOGICA
- The Lymphoma-associated Fusion Tyrosine Kinase ITK-SYK Requires Pleckstrin Homology Domain-mediated Membrane Localization for Activation and Cellular Transformation
- (2009) Sue Rigby et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL
- (2009) A A Mian et al. LEUKEMIA
- Reciprocal t(9;22) ABL/BCR Fusion Proteins: Leukemogenic Potential and Effects on B Cell Commitment
- (2009) Xiaomin Zheng et al. PLoS One
- Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death
- (2008) Raphael Beck et al. BIOCHEMICAL PHARMACOLOGY
- Leukemic challenge unmasks a requirement for PI3K in NK cell-mediated tumor surveillance
- (2008) E. Zebedin et al. BLOOD
- Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression
- (2008) María J. Bueno et al. CANCER CELL
- Oncogene Addiction
- (2008) I. B. Weinstein et al. CANCER RESEARCH
- Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion
- (2008) I. Lahortiga et al. HAEMATOLOGICA
- RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells
- (2008) M Futami et al. LEUKEMIA
- Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin
- (2008) L X Wu et al. LEUKEMIA
- Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases
- (2008) K De Keersmaecker et al. LEUKEMIA
- Kinase Activation and Transformation by NUP214-ABL1 Is Dependent on the Context of the Nuclear Pore
- (2008) Kim De Keersmaecker et al. MOLECULAR CELL
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies
- (2008) William Vainchenker et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started